Using \[99mTc\]-labeled anti-PD-L1 single-domain antibody, this study aims to prospectively measure changes in PD-L1 expression determined with SPECT/CT imaging and correlate these changes with response to anti-PD(L)1 immunotherapy.
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Aged 18 or above
Patients with histologically confirmed NSCLC or melanoma scheduled for PD1/PDL1 immunotherapy alone or in combination with other systemic anti-cancer therapy.
Willingness and ability to comply with scheduled study visits and tests.
You may not be if
Pregnant or lactating women
Concomitant uncontrolled medical conditions
Patients likely to require palliative radiotherapy within the first 12 weeks of treatment or radiotherapy to target lesion(s) received within preceding 42 days
More than 3 months between IHC PDL1 and study recruitment
Patients who have received other systemic anti-cancer therapy within preceding 14 days
Prognosis less than 3 months
Previous anticancer treatment with any checkpoint inhibitor or other immunotherapy, i.e. only immunotherapy naïve patients
Clareo Health | PD-L1 Expression in Cancer (PECan Study).
